Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burton, E. C.
Right arrow Articles by Aldape, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burton, E. C.
Right arrow Articles by Aldape, K. D.
[Cancer Research 62, 6205-6210, November 1, 2002]
© 2002 American Association for Cancer Research


Molecular Biology and Genetics

Genetic Aberrations Defined by Comparative Genomic Hybridization Distinguish Long-Term from Typical Survivors of Glioblastoma1

Eric C. Burton, Kathleen R. Lamborn, Burt G. Feuerstein, Michael Prados, James Scott, Peter Forsyth, Sandra Passe, Robert B. Jenkins and Ken D. Aldape2

Departments of Laboratory Medicine [B. G. F.] and Neurological Surgery [E. C. B., K. R. L., B. G. F., M. P.], University of California, San Francisco, California 94143; Brain Tumor Center, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [K. D. A.]; Department of Medicine, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, 2N4N2 Canada [J. S., P. F.]; and Department of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota 55905 [S. P., R. B. J.]

Glioblastoma (GBM) remains a highly lethal neoplasm, refractory to current therapies. The molecular genetic aberrations most closely related to clinical aggressiveness in GBM have been difficult to identify, perhaps due in part to the short survival range observed in cohorts of GBM patients. To address this, we characterized 39 tumors from rare patients (2–5% of all GBM cases) who experienced long-term survival (>3 years) using comparative genomic hybridization as a genome-wide screen. We then compared the frequency and type of aberrations with those in tumors from 24 typical or short-term survivors [STSs (<1.5 years)]. Losses of 9p and 10 and simple gains of chromosome 7 showed at least trends toward increased frequency in the STS group. Additional aberrations, including loss of 6q and gains of 19q and 20q, were significantly more frequent in the STS group. The presence of 19q loss was exclusive to the long-term survivor (LTS) group. Multivariate analyses indicated that 6q loss, 10q loss, and 19q gain were associated with short-term survival (all P < 0.01). The combination of any two of these three aberrations was seen in 16 of 24 STSs but only 1 of 39 LTSs. This comparison of rare LTSs with STSs (typical GBM survivors) identified 6q loss, 10q loss, and 19q gain, particularly when two or more of these were present, as most closely associated with aggressive clinical behavior in GBM. Loss of 19q may be a marker of long-term survival.




This article has been cited by other articles:


Home page
Genes Dev.Home page
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes & Dev., November 1, 2007; 21(21): 2683 - 2710.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
D. Krex, B. Klink, C. Hartmann, A. von Deimling, T. Pietsch, M. Simon, M. Sabel, J. P. Steinbach, O. Heese, G. Reifenberger, et al.
Long-term survival with glioblastoma multiforme
Brain, October 1, 2007; 130(10): 2596 - 2606.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
W. F Zeng, K. Navaratne, R. A Prayson, and R. J Weil
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme
J. Clin. Pathol., February 1, 2007; 60(2): 218 - 221.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. A. Maher, C. Brennan, P. Y. Wen, L. Durso, K. L. Ligon, A. Richardson, D. Khatry, B. Feng, R. Sinha, D. N. Louis, et al.
Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities
Cancer Res., December 1, 2006; 66(23): 11502 - 11513.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. P. Steinbach, H. -P. Blaicher, U. Herrlinger, W. Wick, T. Nagele, R. Meyermann, M. Tatagiba, M. Bamberg, J. Dichgans, H. -O. Karnath, et al.
Surviving glioblastoma for more than 5 years: The patient's perspective
Neurology, January 24, 2006; 66(2): 239 - 242.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. B.Y. Hui, H. Takano, K.-W. Lo, W.-L. Kuo, C. N.Y. Lam, C. Y.K. Tong, Q. Chang, J. W. Gray, and H.-K. Ng
Identification of a Novel Homozygous Deletion Region at 6q23.1 in Medulloblastomas Using High-Resolution Array Comparative Genomic Hybridization Analysis
Clin. Cancer Res., July 1, 2005; 11(13): 4707 - 4716.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Vandesompele, M. Baudis, K. De Preter, N. Van Roy, P. Ambros, N. Bown, C. Brinkschmidt, H. Christiansen, V. Combaret, M. Lastowska, et al.
Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma
J. Clin. Oncol., April 1, 2005; 23(10): 2280 - 2299.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. M. Nigro, A. Misra, L. Zhang, I. Smirnov, H. Colman, C. Griffin, N. Ozburn, M. Chen, E. Pan, D. Koul, et al.
Integrated Array-Comparative Genomic Hybridization and Expression Array Profiles Identify Clinically Relevant Molecular Subtypes of Glioblastoma
Cancer Res., March 1, 2005; 65(5): 1678 - 1686.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Korshunov, R. Sycheva, and A. Golanov
Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells: The Utility of Fluorescence In situ Hybridization
Clin. Cancer Res., December 1, 2004; 10(23): 7820 - 7826.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. S. Bobola, M. J. Emond, A. Blank, E. H. Meade, D. D. Kolstoe, M. S. Berger, R. C. Rostomily, D. L. Silbergeld, A. M. Spence, and J. R. Silber
Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy
Clin. Cancer Res., December 1, 2004; 10(23): 7875 - 7883.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
R. N. Wiltshire, J. E. Herndon II, A. Lloyd, H. S. Friedman, D. D. Bigner, S. H. Bigner, and R. E. McLendon
Comparative Genomic Hybridization Analysis of Astrocytomas: Prognostic and Diagnostic Implications
J. Mol. Diagn., August 1, 2004; 6(3): 166 - 179.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
J. F. Megyesi, E. Kachur, D. H. Lee, M. C. Zlatescu, R. A. Betensky, P. A. Forsyth, Y. Okada, H. Sasaki, M. Mizoguchi, D. N. Louis, et al.
Imaging Correlates of Molecular Signatures in Oligodendrogliomas
Clin. Cancer Res., July 1, 2004; 10(13): 4303 - 4306.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
D. J. Brat, W. F. Seiferheld, A. Perry, E. H. Hammond, K. J. Murray, A. R. Schulsinger, M. P. Mehta, and W. J. Curran
Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials
Neuro-oncol, April 1, 2004; 6(2): 96 - 103.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.